Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$77.73 USD

77.73
1,733,565

-0.32 (-0.40%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $77.76 +0.04 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

5 Toxic Stocks to Get Rid Of or Play Short to Make Gains

by Zacks Equity Research

Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.

    Zacks Equity Research

    Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?

    by Zacks Equity Research

    Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks Equity Research

      Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

      by Zacks Equity Research

      Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals

        Zacks Equity Research

        5 Toxic Stocks to Dump or Play Short to Make Gains

        by Zacks Equity Research

        Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.

          Zacks Equity Research

          Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4

          by Zacks Equity Research

          Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.

            Sweta Killa headshot

            A Trip to 8-Year Bull Run: What's Up, What's Down

            by Sweta Killa

            While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.

              Zacks Equity Research

              5 Toxic Stocks to Abandon or Play Short Right Now

              by Zacks Equity Research

              In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.

                Zacks Equity Research

                What's Driving Lilly's (LLY) Shares after 2016 Decline?

                by Zacks Equity Research

                After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                  Zacks Equity Research

                  Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook

                  by Zacks Equity Research

                  Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.

                    Zacks Equity Research

                    Lilly's Olumiant Gets Marketing Authorization in Europe

                    by Zacks Equity Research

                    Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

                      Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences

                        Zacks Equity Research

                        What's in Store for Avis Budget (CAR) this Earnings Season?

                        by Zacks Equity Research

                        Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.

                          Zacks Equity Research

                          Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                          by Zacks Equity Research

                          Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies

                            Zacks Equity Research

                            VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?

                            by Zacks Equity Research

                            VASCO Data Security International Inc. (VDSI) is set to report fourth-quarter 2016 results after markets close on Feb 14.

                              Zacks Equity Research

                              Should You Sell Incyte (INCY) Before Earnings?

                              by Zacks Equity Research

                              Incyte (INCY) looks like an exciting pick for investors as it is poised to beat at earnings season.

                                Zacks Equity Research

                                Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?

                                by Zacks Equity Research

                                Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.

                                  Zacks Equity Research

                                  Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?

                                  by Zacks Equity Research

                                  Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.

                                    Zacks Equity Research

                                    5 Toxic Stocks to Dump or Play Short for Gains

                                    by Zacks Equity Research

                                    Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.

                                      Arpita Dutt headshot

                                      5 Drug Stocks Poised to Beat Earnings Estimates in Q4

                                      by Arpita Dutt

                                      Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.

                                        Zacks Equity Research

                                        Can Prothena (PRTA) Pull a Surprise This Earnings Season?

                                        by Zacks Equity Research

                                        Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.

                                          Zacks Equity Research

                                          Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?

                                          by Zacks Equity Research

                                          Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.

                                            Zacks Equity Research

                                            GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?

                                            by Zacks Equity Research

                                            GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.

                                              Zacks Equity Research

                                              Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?

                                              by Zacks Equity Research

                                              Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.

                                                Zacks Equity Research

                                                Incyte and Calithera Enter into Deal for Oncology Candidate

                                                by Zacks Equity Research

                                                Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.

                                                  Zacks Equity Research

                                                  Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%

                                                  by Zacks Equity Research

                                                  Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.